Fast Five Quiz: Helicobacter pylori

B.S. Anand, MD; Steven F. Moss, MD


January 20, 2022

Both ACG guidelines and World Gastroenterology Organisation (WGO) guidelines state that bismuth quadruple therapy consisting of a PPI, bismuth, tetracycline, and a nitroimidazole for 10-14 days is a recommended first-line treatment option. Bismuth quadruple therapy may be especially useful for patients with previous macrolide exposure, in those who are allergic to penicillin, and in regions of high clarithromycin resistance.

Triple therapy consisting of a PPI, clarithromycin, and amoxicillin or metronidazole remains a recommended treatment option only in regions where H pylori clarithromycin resistance is known to be less than 15% and in patients with no previous history of macrolide exposure for any reason. Fourteen days is the usual duration of therapy.

Learn more about the management of H pylori infection.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.